Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Trial Profile

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Panobinostat (Primary) ; Rituximab (Primary) ; Dexamethasone; Filgrastim; Glutamine; Palifermin; Pyridoxine; Pyridoxine
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 21 Mar 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Jun 2021.
    • 21 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top